AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2852540
Drug: Fibre yoghurt
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre yoghurt (150 ml containing lactitol, guar gum, and wheat bran) twice daily for 2 weeks
Trial: 2852540
Drug: Control yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control yoghurt (150 ml without lactitol, guar gum, or wheat bran) twice daily for 2 weeks
Trial: 28211169
Drug: DS-1040 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1040 (0.1 mg to 40 mg, administered as a 0.5-h intravenous infusion or as a 24-h continuous infusion)
Trial: 23472879
Drug: NO₂⁻ infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO₂⁻ infusion (0.31 to 7.8 μmol·min⁻¹)
Trial: 23472879
Drug: NO₂⁻ infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO₂⁻ infusion
Trial: 19085579
Drug: Ciclesonide 640
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 640 micro g/day
Trial: 19085579
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 640 micro g/day
Trial: 10196018
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antioxidant vitamin supplements
Trial: 7757360
Drug: Immunomodulating agents
RxNorm normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulating agents (specific agents not detailed)
Trial: 2184637
Drug: Vincristine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (0.02 to 0.04 mg/kg)
Trial: 2184637
Drug: Vinblastine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine (0.1 to 0.2 mg/kg)
Trial: 760738
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg intravenous injection
Trial: 760738
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg oral dose
Trial: 760738
Drug: Cimetidine treatment
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine treatment (various doses)
Trial: 27873094
Drug: EBR (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBR (50 mg) + GZR (50 mg) for 12 weeks
Trial: 27873094
Drug: EBR (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBR (50 mg) + GZR (100 mg) for 12 weeks
Trial: 27873094
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (noncirrhotic patients)
Trial: 27873094
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (cirrhotic patients)
Trial: 27873094
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (noncirrhotic patients)
Trial: 25191890
Drug: Zirconia implants
RxNorm normalized name: zirconium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zirconia implants (test group)
Trial: 25191890
Drug: Titanium implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium implants (control group)
Trial: 7988012
Drug: Thyroid hormones
RxNorm normalized name: Thyroid hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormones
Trial: 7988012
Drug: Post-load plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-load plasma glucose and insulin concentrations
Trial: 2743469
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline infusion
Trial: 31058633
Drug: Poor oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor oral hygiene
Trial: 25885106
Drug: liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.2 mg QD sc
Trial: 25885106
Drug: metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 1000 mg BID po
Trial: 23612494
Drug: Intranasal Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Botulinum Toxin‐A (75IU Dysport®)
Trial: 21197615
Drug: Oxazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (20 mg p.o.)
Trial: 17531691
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (extended study period)
Trial: 15364759
Drug: nCPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP therapy (during application)
Trial: 15364759
Drug: nCPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP therapy (before application)
Trial: 11589843
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine 5 mg
Trial: 9647968
Drug: Esterified estrogens
RxNorm normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified estrogens plus methyltestosterone for four and eight weeks of daily drug administration
Trial: 9647968
Drug: Esterified estrogens
RxNorm normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified estrogens alone for four and eight weeks of daily drug administration
Trial: 7991990
Drug: c-erbB-2 protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c-erbB-2 protein levels during chemotherapy in recurrent or inoperable metastatic disease
Trial: 2647667
Drug: Relaxation training
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation training (stepwise relaxation/hypnosis/autogenic training/cognitive behavior therapy)
Trial: 2647667
Drug: Micro-electrical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-electrical therapy (TENS/Neurotransmitter Modulation)
Trial: 2647667
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment (combination of any of the above two treatments)
Trial: 2647667
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term intervention (15 or less treatments)
Trial: 2647667
Drug: Long term
RxNorm normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term intervention (greater than 15 treatments)
Trial: 31955968
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine combined with 0.3 μg/mL sufentanil
Trial: 31745043
Drug: Mouthwash containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash containing essential oils and curcumin (MEC) as an adjunct to scaling and root planing (SRP)
Trial: 31745043
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine mouthwash as an adjunct to scaling and root planing (SRP)
Trial: 24668575
Drug: Intrathecal 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 0.5% isobaric levobupivacaine with 25 mcg fentanyl
Trial: 17129547
Drug: Prednisone 40
RxNorm normalized name: prednisone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg daily for 4 weeks, followed by 2 weeks without treatment, and lamivudine 150 mg daily for 4 weeks; followed by lamivudine plus interferon alfa 2b (10 MIU every other day) for 24 weeks and continuous lamivudine 150 mg daily to complete 58 weeks
Trial: 17129547
Drug: Lamivudine 150
RxNorm normalized name: lamivudine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 150 mg daily for 4 weeks plus interferon alfa 2b (10 MIU every other day) for 24 weeks, without prednisone
Trial: 15361771
Drug: Daily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fish meal
Trial: 9309708
Drug: Dextromethorphan (36‐38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (36‐38 mg/kg/day)
Trial: 3739805
Drug: Medium drinkers
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium drinkers consuming an experimental dose similar to their usual dose
Trial: 3739805
Drug: Heavy drinkers
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy drinkers consuming a dose lower than their usual dose
Trial: 22658300
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial volume index (LAVI) > 32 ml/m(2)
Trial: 20886787
Drug: Medication (Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Sodium Hyaluronate eye drops, 1 drop three times per day)
Trial: 10721929
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg iron as ferrous sulfate daily from Monday to Friday
Trial: 10721929
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg iron as ferrous sulfate 2 d/wk and 3 d placebo (intermittent)
Trial: 9188929
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (200 micrograms once daily for 4 weeks)
Trial: 9188929
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg once daily for 4 weeks)
Trial: 3549875
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg atropine
Trial: 26331692
Drug: GW406381 (COX-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW406381 (COX-2 inhibitor)
Trial: 20457702
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment (no identified aetiology)
Trial: 18971490
Drug: Early insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early insulin therapy (continuous infusion of insulin at a dose of 0.05 U/kg/hour with 20% dextrose support)
Trial: 24281139
Drug: Early insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early insulin therapy
Trial: 12634885
Drug: Antiarrhythmic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic therapy (e.g. amiodarone)
Trial: 12634885
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy and angiotensin converting enzyme inhibitors
Trial: 9684946
Drug: 300 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/kg Hypericum extract (WS 5572, containing 5% hyperforin) in rats
Trial: 9684946
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg hypericum extracts (14.8 mg hyperforin) in human volunteers
Trial: 9684946
Drug: Repeated dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dose of 3 x 300 mg/day of the extract in human volunteers
Trial: 9684946
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of 900 or 1200 mg of extract in human volunteers
Trial: 2965126
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg teicoplanin given intravenously on induction of anaesthesia
Trial: 2965126
Drug: Three perioperative
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three perioperative injections of cefuroxime
Trial: 26970533
Drug: Maintenance Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance Rituximab (MR) - single dose rituximab every 3 months until treatment failure
Trial: 26970533
Drug: Retreatment Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Retreatment Rituximab (RR) - rituximab weekly for 4 weeks at the time of each progression until treatment failure
Trial: 25500487
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg canagliflozin
Trial: 25802729
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg canagliflozin
Trial: 16828533
Drug: Propranolol HCl
RxNorm normalized name: propranolol HCl
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol HCl administered before acquisition
Trial: 16828533
Drug: Propranolol HCl
RxNorm normalized name: propranolol HCl
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol HCl administered following extinction trials
Trial: 15272106
Drug: Paroxetine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (selective serotonin reuptake inhibitor antidepressant)
Trial: 11383378
Drug: Rosuvastatin (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (1, 2.5, 5, 10, 20, 40, and 80 mg/day)
Trial: 9241125
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg)
Trial: 9241125
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Probucol + Multivitamins)
Trial: 9241125
Drug: Multivitamins (30,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamins (30,000 IU beta carotene, 500 mg vitamin C, 700 IU vitamin E)
Trial: 30567603
Drug: Twice-daily text-message
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily text-message reminders on case management of malaria
Trial: 30567603
Drug: Twice-daily text-message
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily text-message reminders on case management of malaria, pneumonia, and diarrhoea
Trial: 25058346
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg BID plus standard dose of weekly paclitaxel
Trial: 15207761
Drug: ibandronate therapy
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibandronate therapy (6 or 12 mg)
Trial: 2857361
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen at 2 atmospheres absolute for 90 min daily for a total of 20 exposures
Trial: 27347862
Drug: Hip-focused muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip-focused muscle strengthening treatment program
Trial: 27347862
Drug: Knee-focused muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee-focused muscle strengthening treatment program
Trial: 18814197
Drug: Caregiver education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver education and training intervention delivered over five, weekly, half‐hour sessions consisting of assessment, basic education about dementia, and training regarding specific problem behaviors.
Trial: 16484875
Drug: Rofecoxib 12.5
RxNorm normalized name: rofecoxib 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 12.5 mg per day
Trial: 16484875
Drug: Nabumetone 500
RxNorm normalized name: nabumetone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 500 mg twice a day
Trial: 12941090
Drug: 2% hydroquinone‐cyclodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% hydroquinone‐cyclodextrin formulation applied once daily for 2 months
Trial: 10711913
Drug: Lamotrigine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (300 mg by mouth)
Trial: 31246555
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise at the same intensities as RHG and cycling
Trial: 27008287
Drug: C-arm guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-arm guided epidural injection of local anesthetic and corticosteroid
Trial: 17366252
Drug: More problems
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More problems with drugs
Trial: 16295212
Drug: Melatonin 0.3
RxNorm normalized name: melatonin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 0.3 mg
Trial: 16295212
Drug: Melatonin 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3.0 mg
Trial: 11600532
Drug: Melatonin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 0.1 mg
Trial: 22949577
Drug: osmotic‐release oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: osmotic‐release oral system methylphenidate (OROS‐MPH) + transdermal nicotine replacement + brief cessation counseling
Trial: 22949577
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + transdermal nicotine replacement + brief cessation counseling
Trial: 18791983
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group psychotherapy in combination with open methylphenidate treatment (Medikinet retard ®) titrated upward individually until the maximum dose of 1.3 mg/kg/day
Trial: 16548956
Drug: Diclofenac‐Hand group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac‐Hand group (diclofenac transdermal patch on the dorsum of hand and placebo patch on the buttock)
Trial: 16548956
Drug: Diclofenac‐Buttock group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac‐Buttock group (placebo patch on the dorsum of the hand and diclofenac transdermal patch on the buttock)
Trial: 16548956
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo adhesive patch on both the dorsum of hand and the buttock)
Trial: 2908720
Drug: celiprolol 400
RxNorm normalized name: celiprolol 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol 400 mg
Trial: 2908720
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg
Trial: 30787294
Drug: RV144 HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV144 HIV vaccine
Trial: 27468593
Drug: Ketoprofen (1.60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (1.60 mg/mL)
Trial: 25245482
Drug: Traditional Swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Swallowing (TS) therapy
Trial: 25245482
Drug: Combined NMES/TS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined NMES/TS therapy
Trial: 25245482
Drug: Oropharyngeal neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal neuromuscular electrical stimulation (NMES) therapy
Trial: 22989795
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n=81)
Trial: 17265406
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for bacterial pneumonia (specifics not provided)
Trial: 12428086
Drug: DX-9065a (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DX-9065a (1 mg bolus + 0.25 mg/h x 2 h, followed by 1 mg bolus + 0.625 mg/h x 2 h, and a final 1 mg bolus + 1.25 mg/h x 2 h)
Trial: 12428086
Drug: DX-9065a +
RxNorm normalized name: DX-890
DrugBank: Depelestat (DB17873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DX-9065a + ASA (pre-treatment)
Trial: 12428086
Drug: Enoxaparin +
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin + ASA (1 mg/Kg s. c + 162 mg/day x 3 days)
Trial: 9454525
Drug: Troglitazone 200
RxNorm normalized name: troglitazone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 200 mg/d
Trial: 8578993
Drug: Caffeine (Cf,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (Cf, 50 mg/g of ointment or solution)
Trial: 8578993
Drug: Interferon (IFN,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN, 5 x 10(4) IU/g)
Trial: 7237896
Drug: Propranolol with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol with either diuretic
Trial: 31507249
Drug: Other medications
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other medications for gout treatment
Trial: 19159947
Drug: Cinnamon supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon supplementation (3 g day(‐1))
Trial: 12151917
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 20 mg
Trial: 12151917
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 40 mg
Trial: 12151917
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 4 mg